HC Wainwright & Co. Maintains Buy on Gain Therapeutics, Lowers Price Target to $9
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Raghuram Selvaraju has maintained a Buy rating on Gain Therapeutics (NASDAQ:GANX) but has reduced the price target from $10 to $9.

December 04, 2023 | 11:47 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Gain Therapeutics' stock may see a mixed reaction as the Buy rating is maintained but the price target is lowered from $10 to $9 by HC Wainwright & Co.
While the maintenance of a Buy rating is positive, the reduction in the price target could signal a tempered expectation of future performance, which might cause uncertainty among investors. The impact is likely neutral in the short term as the positive and negative news could balance each other out.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100